Thrombosis and haemostasis最新文献

{"title":"Clinical Characteristics and Early Outcomes of Acute Pulmonary Embolism Presenting with Syncope.","authors":"Marina López-Rubio, Victor Manuel Martínez-Castilla, Andrea Cobo-Bustamante, Lorena Sanz-Tejeiro, Rubén Alonso-Beato, Lucía Ordieres-Ortega, Crhistian-Mario Oblitas, Luis Antonio Álvarez-Sala Walther, Francisco Galeano-Valle, Pablo Demelo-Rodriguez","doi":"10.1055/a-2949-8251","DOIUrl":"https://doi.org/10.1055/a-2949-8251","url":null,"abstract":"<p><strong>Background: </strong>The prognostic significance of syncope in patients with acute pulmonary embolism (PE) remains uncertain. We assessed its association with early outcomes and explored whether distinct clinical phenotypes could be identified within this group.</p><p><strong>Methods: </strong>We analyzed a prospectively collected single-center cohort of patients with confirmed symptomatic PE diagnosed between 2010 and 2025, grouped by syncope at presentation. The primary outcome was a 30-day composite of all-cause mortality, major bleeding, and recurrent venous thromboembolism. Associations were estimated using inverse probability of exposure weighting. Estimand A balanced baseline confounders, whereas Estimand B additionally balanced measured markers of acute severity. Within the syncope subgroup, exploratory clustering used 13 baseline clinical variables.</p><p><strong>Results: </strong>Among 2,331 patients with PE, 329 (14.1%) presented with syncope. Under Estimand A, syncope was associated with a 14.0-percentage-point higher risk of the composite outcome (95% confidence interval [CI]: 9.0-19.6; risk ratio [RR]: 2.71, 95% CI: 2.02-3.52). Under Estimand B, the association was substantially attenuated, with a risk difference of 5.2 percentage points (95% CI: - 0.2 to 10.6; RR: 1.54, 95% CI: 0.98-2.19). A similar attenuation was observed for all-cause mortality and major bleeding. Exploratory clustering identified four phenotypes, none of which met the prespecified criteria for internal stability.</p><p><strong>Conclusion: </strong>In acute PE, syncope identifies patients at higher risk of early adverse outcomes. This association was substantially attenuated after accounting for measured acute severity, suggesting that syncope mainly marks a more severe initial presentation rather than carrying prognostic information independent of severity.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mouse Models to Study Von Willebrand Factor in Hemostasis: A Scoping Review.","authors":"Veronica DeYoung, Hassan Masood, Peter Andrisani, Arthane Kodeeswaran, Jaskirat Arora, Taylor Sparring, Natasha Savic, Jonathan L Babulic, Patricia C Liaw, Davide Matino, Alison Fox-Robichaud, Colin A Kretz","doi":"10.1055/a-2941-2718","DOIUrl":"10.1055/a-2941-2718","url":null,"abstract":"<p><strong>Background: </strong>Von Willebrand factor (VWF) and its primary molecular regulator, ADAMTS13, play an important role in hemostasis. Their dysfunction has been increasingly linked to numerous bleeding, thrombotic, and inflammatory conditions. Murine bleeding models are widely used to study their role and assess therapeutic efficacy of targeted agents. Despite this, no review has systematically identified and compared bleeding models proven to involve VWF or ADAMTS13 in vivo. This scoping review addresses this gap by identifying models, associated outcomes, and evaluating methodological inconsistencies that may impact translatability.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted to identify studies using murine models of hemostasis from inception to October 2024. Two reviewers independently screened articles and extracted data on mouse characteristics, bleeding induction methods, and VWF or ADAMTS13-related findings.</p><p><strong>Results: </strong>A total of 35 studies published between 1997 and 2024 were included; 40.0% utilized C57BL/6J mice and 40.0% of models used both sexes. Fourteen (40.0%) studies did not report the mouse supplier, and 20.0 and 80.0% did not report the age and weight of mice, respectively. Most studies (91.4%) used the tail tip transection model, 5.7% employed saphenous vein bleed, and 5.7% performed tail vein transection. Key methodological variations pertained to bleeding quantification, maximum observation time, and length of tail tip removed.</p><p><strong>Conclusion: </strong>This review highlights that most studies assessing VWF-related hemostasis use a single model, but there is methodological variability, limiting reproducibility and translational relevance. Standardized protocols and collaborative efforts to establish consensus guidelines are urgently needed to improve cross-study comparisons to strengthen preclinical therapeutic testing.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":""},"PeriodicalIF":5.2,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148798131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood Levels and Composition of Leukocyte-Platelet Aggregates in Inflammatory Diseases of Various Etiologies.","authors":"Alina D Peshkova, Shakhnoza M Saliakhutdinova, Khetam Sounbuli, Izabella A Andrianova, Rustem I Litvinov, John W Weisel","doi":"10.1055/a-2742-3449","DOIUrl":"10.1055/a-2742-3449","url":null,"abstract":"<p><strong>Background: </strong>Leukocyte-platelet aggregates (LPAs) play a crucial role in the pathogenesis of inflammatory diseases, linking pathological immune responses with thrombosis.</p><p><strong>Material and methods: </strong>The levels of LPAs, their composition, and cellular reactivity were determined in patients with distinct inflammatory conditions, namely coronavirus disease 2019 (COVID-19), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), compared with healthy controls. Flow cytometry was used to identify cell types and measure LPA levels in the blood. The ability of platelets, neutrophils, and monocytes to form additional LPAs in response to hyperstimulation with phorbol-12-myristate-13-acetate (PMA) was assessed. Coaggregation of isolated neutrophils and platelets in vitro was visualized using scanning electron microscopy. Blood tests included coagulation, hematology, biochemistry, and immunology.</p><p><strong>Results: </strong>LPA levels were significantly higher in all patient groups compared with controls, with variations in the composition: neutrophil-platelet aggregates predominated in the COVID-19 patients, whereas monocyte-platelet aggregates prevailed in the blood of RA and SLE patients. Platelet-to-leukocyte ratios within aggregates varied in a broad range with a substantial prevalence of platelets over leukocytes. Morphological analysis revealed coaggregation of platelets with neutrophils, including relatively large homotypic platelet aggregates associated with one or two neutrophils. In PMA-treated pathological blood samples from COVID-19, RA, and SLE patients, the ability to form additional LPAs over the patients' baseline level was reduced compared with normal blood samples, indicating impaired reactivity (exhaustion) of neutrophils and monocytes in all patient groups.</p><p><strong>Conclusion: </strong>This study highlights distinct changes in the number and composition of LPAs in inflammatory diseases of various etiologies associated with altered functionality of the innate immune cells.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"948-961"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145506716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous Thromboembolism and Vascular Access Thrombosis in Patients on Hemodialysis: Incidence, Risk Factors, and Use of Antithrombotic Agents.","authors":"Oliver Königsbrügge, Renate Klauser-Braun, Sabine Schmaldienst, Matthias Lorenz, Ingrid Pabinger, Marcus Säemann, Cihan Ay","doi":"10.1055/a-2700-6368","DOIUrl":"10.1055/a-2700-6368","url":null,"abstract":"<p><strong>Background: </strong>Patients with end-stage kidney disease on hemodialysis (HD) have an increased risk of venous thromboembolism (VTE) and HD-specific vascular access thrombosis (VAT). We aimed to capture the incidence of VTE and VAT events and investigate risk factors for VTE and VAT occurrence, including antithrombotic agent use.</p><p><strong>Methods: </strong>Prevalent patients on maintenance HD were recruited into a prospective, population-based, observational cohort study in Vienna, Austria. During a maximum follow-up of 45 months, the occurrence of VTE, defined as deep vein thrombosis, catheter- or noncatheter-associated, and pulmonary embolism, or VAT, defined as thrombotic occlusion of an arteriovenous fistula or graft, was recorded. Risk factors for thrombotic events were analyzed by multivariable competing risk regression.</p><p><strong>Results: </strong>VTE and VAT events occurred with an incidence rate of 1.7 (95% confidence interval [CI]: 1.2-2.6) and 7.6 per 100 person-years (95% CI: 6.3-9.3), respectively. The 30-day case fatality rates were 20.8 and 4.1% for VTE and VAT events, respectively. Prior VAT (hazard ratio [HR]: 3.07, 95% CI: 1.33-7.11, <i>p</i> = 0.009) and nephrectomy (HR: 6.53, 95% CI: 2.23-19.14, <i>p</i> = 0.001) were significantly associated with increased risk of VTE occurrence. Prior VAT was associated with a 1.8-fold (95% CI: 1.18-2.65, <i>p</i> = 0.006) and nephrectomy with a 2.8-fold increased risk of VAT occurrence (95% CI: 1.45-5.57, <i>p</i> = 0.002). Patients on vitamin K antagonists were protected from VTE (HR: 0.001, 95% CI: <0.01- < 0.01, <i>p</i> < 0.001) compared with nonusers but had no benefit with regard to VAT events.</p><p><strong>Conclusion: </strong>Identifying patients at high risk of thrombotic complications using risk factors, such as a history of nephrectomy and prior thrombotic events, may facilitate preventive measures.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"965-973"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry.","authors":"Edelgard Lindhoff-Last, Inka Wiegratz, Olivia Ott, Yvonne Weil, Christoph Sucker, Susan Halimeh, Holger Seidel, Christian Schambeck, Konstantin Kirchmayr, Eva Herrmann","doi":"10.1055/a-2724-4458","DOIUrl":"10.1055/a-2724-4458","url":null,"abstract":"<p><strong>Background: </strong>Heavy menstrual bleeding (HMB) is a common complication of anticoagulant therapy in menstruating women with venous thromboembolism (VTE). Direct oral anticoagulants (DOAC) used for VTE treatment may differ in their menstrual bleeding profiles. Therefore, the prospective multicenter noninterventional investigator-initiated HEMBLED registry (HE: avy M: enstrual BLE: eding in patients treated with D: OAC) was performed to analyze spontaneous menstrual bleeding in women treated with therapeutic DOAC doses.</p><p><strong>Methods: </strong>A modified pictorial blood assessment chart (PBAC) score was used to define the severity of menstrual bleeding. Patients were only included when they did not use hormonal or intrauterine contraception methods. The prospective follow-up was 4 months. The primary endpoint was the comparison of the PBAC scores between the individual DOAC groups.</p><p><strong>Results: </strong>Overall, 73 patients with 213 monthly assessments of the PBAC scores were analyzed. Patients were on average 35 years old and were anticoagulated with apixaban (62%), rivaroxaban (26%), edoxaban (7%), or dabigatran (6%). The PBAC scores of the rivaroxaban group (mean: 145 points) were significantly increased by 54% compared with the apixaban group (mean: 93 points, <i>p</i> = 0.0193). HMB (PBAC score > 100 points) at least once was detected in 53% of the apixaban group compared with 79% of the rivaroxaban group (<i>p</i> = 0.0913). The duration of menstrual bleeding was numerically shorter in the apixaban group compared with the rivaroxaban group (<i>p</i> = 0.1894).</p><p><strong>Conclusion: </strong>DOAC differ in their influence on the intensity of spontaneous menstrual bleeding. This should be taken into account when advising young women with VTE who need an oral anticoagulant.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"974-982"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145507046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetics, Hemostatic Efficacy, and Safety of a New Human Fibrinogen Concentrate in Adult and Pediatric Patients with Congenital Fibrinogen Deficiency.","authors":"Claudia Djambas Khayat, Amal El-Beshlawy, Balkis Meddeb, Abderrahim Khelif, Wolfgang Miesbach, Sonia Adolf, Heike Boehm, Silke Aigner, Salomon Abraha, Fabian Bohlaender, Joerg Schuettrumpf","doi":"10.1055/a-2715-2994","DOIUrl":"10.1055/a-2715-2994","url":null,"abstract":"<p><p>Congenital fibrinogen deficiencies are rare coagulopathies which are treated by fibrinogen concentrates. This trial investigated the pharmacokinetic/pharmacodynamic (PK/PD) parameters, and surrogate efficacy and safety of a new human fibrinogen concentrate (HFC), BT524, in patients with congenital afibrinogenemia or severe hypofibrinogenemia.This prospective, multi-national, open-label, single-arm PK/PD trial evaluated PK/PD parameters of HFC (part 1; phase I) and HFC as on-demand treatment or prophylaxis for bleeding events (part 2; phase III). In part 1, patients received a single-dose of HFC (70 mg/kg body weight [BW]). PK/PD parameters were calculated using a PK/PD model and non-compartmental analysis. Fibrinogen antigen (FiAg) levels were determined over 14 days by immunonephelometry and fibrinogen activity (FiAc) by Clauss assay. The efficacy variable was mean change in maximum clot firmness (MCF) analyzed by thromboelastometry. Safety parameters were evaluated for 49 days.A total of 27 patients (<i>n</i> = 15 adults, <i>n</i> = 12 children) were treated with HFC. For FiAg, mean (SD) PK parameters were: C_max 1.81 (0.42) g/L, AUC_0-∞ 173 (45.4) g*h/L, and t_1/2 67.9 (15.3) h. For FiAc, they were C_max 1.26 (0.4) g/L, AUC_0-∞ 104 (33.5) g*h/L, and t_1/2 60.3 (13.3) h. In adults, MCF significantly increased 1 h after HFC infusion (11.1 (5.1) mm; <i>P</i> < 0.0001; 95% CI: 9.33-14.47). In pediatrics, mean increase in range was 9.3 to 16.5 mm. Treatment-related adverse events were rare, with one mild increase in fibrin D-dimer. No thromboembolic events, hypersensitivity, or allergic reactions were observed.HFC effectively increased FiAg levels and FiAc, improved clot firmness, and showed a favorable safety and tolerability profile in adult and pediatric patients with congenital fibrinogen deficiency.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"919-929"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-Leukocyte Aggregates: Targeting the Crosstalk.","authors":"Daniel I Simon, Edward F Plow","doi":"10.1055/a-2784-0699","DOIUrl":"10.1055/a-2784-0699","url":null,"abstract":"","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"962-964"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145960353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Left Ventricular Thrombus After Myocardial Infarction: The Potential Role of Inherited Thrombophilia.","authors":"Francisco Ujueta, Behnood Bikdeli","doi":"10.1055/a-2827-2069","DOIUrl":"10.1055/a-2827-2069","url":null,"abstract":"","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"908-910"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147469235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals.","authors":"Georges Jourdi, Claire Flaujac, Emmanuel De Maistre, Nicolas Gendron, Valérie Eschwège, Laetitia Mauge","doi":"10.1055/a-2695-2674","DOIUrl":"10.1055/a-2695-2674","url":null,"abstract":"<p><p>Although inherited and acquired thrombophilia screening should ideally be performed outside of any direct oral anticoagulant (DOAC) therapy, it is sometimes performed in patients who are anticoagulated. However, DOACs have been shown to interfere with many hemostasis tests, with a risk of false-positive/negative results in lupus anticoagulant testing and overestimation of natural coagulation inhibitor levels, which may lead to misdiagnosis. Devices have been developed to overcome DOAC interference but their role in thrombophilia testing is not clearly established. In this comprehensive review, we provide an in-depth overview of the literature on the impact of DOACs on thrombophilia assays, including lupus anticoagulant testing, antithrombin, protein C, and protein S assessment. DOACs can interfere with the results of thrombophilia testing even at low concentrations; therefore information on current or recently discontinued anticoagulant treatment should be provided when prescribing thrombophilia testing. Data on the usefulness of the most used DOAC removal systems based on activated charcoal to circumvent DOAC interference are heterogeneous. They are summarized in this critical review. Although activated charcoal could be useful to remove DOACs from plasma prior to thrombophilia testing, it may not be completely effective, particularly with apixaban. Hence, and in the light of the available literature, we provide 22 practical proposals for reliable thrombophilia testing and accurate result interpretation in samples from patients receiving DOACs and treated in vitro with activated charcoal.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"867-882"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13521663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Factor XI is Associated with First and Recurrent Left Atrial Appendage Thrombus of Unknown Origin.","authors":"Aleksandra Banaś, Szymon Glanowski, Michał Ząbczyk, Elżbieta Paszek, Anetta Undas","doi":"10.1055/a-2703-4109","DOIUrl":"10.1055/a-2703-4109","url":null,"abstract":"<p><strong>Background: </strong>Formation of denser and poorly lysable fibrin networks characterizes patients with left atrial appendage thrombus (LAAT) of unknown origin. Elevated factor (F)XI is associated with thromboembolism, including left ventricular thrombus. We investigated whether FXI is increased in LAAT and might predispose to its recurrence and complications.</p><p><strong>Methods: </strong>In a case-control study, we studied 36 consecutive patients with LAAT of unknown origin following thrombus resolution, versus 36 age-, sex-, and diabetes-matched controls, all without current anticoagulant treatment. Plasma FXI levels were assessed, along with von Willebrand factor (vWF), clot permeability (K_s), clot lysis time (CLT), fibrinolysis proteins, thrombin generation, and platelet markers. Ischemic cerebrovascular events and LAAT recurrence were evaluated during a median follow-up of 10 years.</p><p><strong>Results: </strong>FXI levels were 14% higher in the LAAT group compared with controls (<i>p</i> < 0.001). FXI >120% was more common in the former group (<i>p</i> = 0.0015). Current smoking and fibrinogen were associated with FXI >120%. In LAAT patients, FXI correlated positively with fibrinogen and CLT, while inversely with vWF and K_s. Most recurrent LAAT (<i>n</i> = 10 out of 11 in total) or cerebrovascular events (<i>n</i> = 18 out of 23 in total) occurred in patients with baseline FXI >120% (both <i>p</i> < 0.001). FXI was associated with LAAT recurrence (OR for 10% = 2.73, 95% CI: 1.32-5.66) and cerebrovascular events (OR for 10%: 1.79, 95% CI: 1.06-3.04).</p><p><strong>Conclusion: </strong>Higher FXI is associated with LAAT of unknown origin, its recurrence and occurrence of cerebrovascular events following anticoagulation withdrawal. Further studies are needed to evaluate whether FXI may help identify patients with LAAT who require prolonged anticoagulation.</p>","PeriodicalId":23036,"journal":{"name":"Thrombosis and haemostasis","volume":" ","pages":"911-918"},"PeriodicalIF":5.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145193042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}